Evidence map›Paper›PMID 41740004›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

A Mitochondria-Specific Nanomedicine for Synergistic Chemo-Photothermal Therapy and Immunogenic Activation Against Breast Cancer.

Min Li, Jiangqi Feng, Junyang Zhuang, Qingguo Zhong, Yanda Li, Yanzhuo Lv, Shaoteng Huang, Xiangyu Huang, Mingbo Zhang, Xiaofeng Cai and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Min LiFujian Key Laboratory of Drug Target Discovery and Structural and Functional Research, School of Pharmacy, Fujian Medical University, Fuzhou, China.
Jiangqi FengDepartment of Chemistry, University College London, London, UK.
Junyang ZhuangFujian Key Laboratory of Drug Target Discovery and Structural and Functional Research, School of Pharmacy, Fujian Medical University, Fuzhou, China.
Qingguo ZhongSchool of Medicine, Fuzhou University, Fuzhou, China.
Yanda LiFujian Key Laboratory of Drug Target Discovery and Structural and Functional Research, School of Pharmacy, Fujian Medical University, Fuzhou, China.
Yanzhuo LvFujian Key Laboratory of Drug Target Discovery and Structural and Functional Research, School of Pharmacy, Fujian Medical University, Fuzhou, China.
Shaoteng HuangFujian Key Laboratory of Drug Target Discovery and Structural and Functional Research, School of Pharmacy, Fujian Medical University, Fuzhou, China.
Xiangyu HuangFujian Key Laboratory of Drug Target Discovery and Structural and Functional Research, School of Pharmacy, Fujian Medical University, Fuzhou, China.
Mingbo ZhangFujian Key Laboratory of Drug Target Discovery and Structural and Functional Research, School of Pharmacy, Fujian Medical University, Fuzhou, China.
Xiaofeng CaiFujian Key Laboratory of Drug Target Discovery and Structural and Functional Research, School of Pharmacy, Fujian Medical University, Fuzhou, China.
Yuxin WangFujian Key Laboratory of Drug Target Discovery and Structural and Functional Research, School of Pharmacy, Fujian Medical University, Fuzhou, China.
Wenping ChenFujian Key Laboratory of Drug Target Discovery and Structural and Functional Research, School of Pharmacy, Fujian Medical University, Fuzhou, China.
Zhenyu DuanDepartment of Radiology, Huaxi MR Research Center (HMRRC), Institution of Radiology and Medical Imaging, Frontiers Science Center for Disease-Related Molecular Network, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Zhou ChenFujian Key Laboratory of Drug Target Discovery and Structural and Functional Research, School of Pharmacy, Fujian Medical University, Fuzhou, China.
Kui LuoDepartment of Radiology, Huaxi MR Research Center (HMRRC), Institution of Radiology and Medical Imaging, Frontiers Science Center for Disease-Related Molecular Network, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.ORCID https://orcid.org/0000-0002-3536-1485
Ning LiFujian Key Laboratory of Drug Target Discovery and Structural and Functional Research, School of Pharmacy, Fujian Medical University, Fuzhou, China.

Funding

Fujian Science and Technology Innovation Joint Fund Project 2024Y9097Guangxi Key Laboratory of Molecular Medicine in Liver Injury and Repair GXLIRMMKL-K202403National Natural Science Foundation of China 51703245Natural Science Foundation of Fujian Province 2024J01499
6 · The paper itself

Abstract

The presence of "cold" tumors in the tumor site is characterized with poor immune cell infiltration and resistance to conventional cancer therapies. To address these challenges, we developed an amphiphilic peptide dendrimer-based multifunctional drug delivery system for integrating photothermal therapy (PTT), chemotherapy, and immunogenic cell death (ICD) to overcome the limitations of single-modality treatments. Efficient drug delivery via the nanoplatform is realized through improving circulation stability, facilitating accumulation and penetration in tumor tissues, promoting cellular uptake, and accelerating tumor microenvironment-responsive drug release. The mitochondria-targeting property is derived from a mitochondria-specific photothermal agent and a lipophilic cationic structure in the amphiphilic dendrimer, and it allows selective mitochondrial accumulation and disruption of the mitochondrial function. In vivo and in vitro studies confirm that PTT synergizes with chemotherapy to significantly enhance therapeutic efficacy, effectively induce ICD to modulate the tumor microenvironment, and strengthen antitumor responses. This nanoplatform enhances drug delivery, induces mitochondrial dysfunction, and achieves potent therapeutic effects, therefore, it could be fine-tuned to become versatile for combination cancer therapies.

Indexed as

Breast NeoplasmsDrug Delivery SystemsMitochondriaNanomedicinePhotothermal TherapyAnimalsAntineoplastic AgentsCell Line, TumorCombined Modality TherapyFemaleHumansMiceTumor MicroenvironmentAntineoplastic Agentsamphiphilic peptide dendrimerimmunogenic cell deathmitochondria‐specificsynergic therapiestranscytosis

Identifiers

PMID41740004
PMCPMC13205596

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.